Endothelin receptor antagonist

Takuya Kishi, Kenji Sunagawa

    Research output: Contribution to journalReview articlepeer-review

    1 Citation (Scopus)

    Abstract

    Pulmonary arterial hypertension(PAH) is an uncommon disease characterised by a progressive increase in pulmonary vascular resistance. An imbalance between vasoconstrictor/vasodilator activities could be responsible for altered pulmonary vascular tone and structure. In PAH patients, endothelin are increased. Restoration of this imbalance by targeted therapies such as endothelin receptor antagonists should further improve treatment options for the management of PAH. Current treatment algorithms for PAH recommend bosentan as first-line treatment for PAH in functional class III. Recent many trials suggested that endothelin receptor antagonist, bosentan, caused good results in idiopathic PAH and PAH associated with chronic thromboembolism, collagen diseases, and congenital heart diseases.

    Original languageEnglish
    Pages (from-to)2152-2156
    Number of pages5
    JournalNippon rinsho. Japanese journal of clinical medicine
    Volume66
    Issue number11
    Publication statusPublished - Nov 2008

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Fingerprint Dive into the research topics of 'Endothelin receptor antagonist'. Together they form a unique fingerprint.

    Cite this